Optimal use of prostate specific antigen for prostate cancer screening

Ranko Miočinović; Uroš Bumbaširević; Miroslav L. Djordjević; Nebojša Bojanić; Bogomir Milojević; Cane Tulić; Andrew J. Stephenson

doi:10.2298/2653

Ranko Miočinović Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Avenue / Q10-1, Cleveland, Ohio, USA
Uroš Bumbaširević Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia
Miroslav L. Djordjević Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Nebojša Bojanić Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia
Bogomir Milojević Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia
Cane Tulić Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Andrew J. Stephenson Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA

DOI: https://doi.org/10.2298/2653

Keywords: prostate neoplasms, prostate-specific antigen, diagnosis, risk assessment,

References

Stephenson AJ, Kuritzky L, Campbell SC. Screening for urologic malignancies in primary care: pros, cons, and recommenda-tions. Cleve Clin J Med 2007;74(Suppl 3): S6−14.

Kuriyama M, Wang MC, Lee CL, Killian CS, Papsidero LD, Inaji H, et al. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst 1982; 68(1): 99−105.

Killian CS, Yang N, Emrich LJ, Vargas FP, Kuriyama M, Wang MC, et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985; 45(2): 886−91.

Siddall JK, Cooper EH, Newling DW, Robinson MR, Whelan P. An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. Eur Urol 1986; 12(2): 123−30.

Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267(16): 2215−20.

Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schönitzer D, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58(3): 417−24.

Andriole GL, Crawford DE, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360(13): 1310−9.

Andriole GL, Crawford DE, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Pros-tate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104(2): 125−32.

Schröder FH. PSA screening: a review of recent studies. Eur J Cancer 2009; 45(Suppl 1): 402−4.

Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a random-ized European study. N Engl J Med 2009; 360(13): 1320−8.

Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366(11): 981−90

Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27(26): 4300−5.

Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012; 187(4): 1259−65.

Moyer VA. Screening for Prostate Cancer: US Preventive Ser-vices Task Force Recommendation Statement.. Ann Intern Med 2012; 157(2): 120−34.

Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson J, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins meas-ured at age 44 to 50 years. J Clin Oncol 2007; 25(4): 431−6.

Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010; 341: c4521.

Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years. J Urol 2004; 172(4 Pt 1): 1297−301.

Stephenson AJ, Abouassaly R, Klein EA. Chemoprevention of prostate cancer. Urol Clin North Am 2010; 37(1): 11−21.

Miocinovic R, Jones SJ, Pujara AC, Klein EA, Stephenson AJ. Ac-ceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: im-proved outcomes with stringent enrollment criteria. Urology 2011; 77(4): 980−4.

Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate can-cer. JAMA 2005; 293(17): 2095−101.

Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, Schröder FH, et al. Lead times and overdetection due to pros-tate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95(12): 868−78.

Roobol MJ, Roobol DW, Schröder FH. Is additional testing neces-sary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, sec-tion Rotterdam). Urology 2005; 65(2): 343−6.

Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ. Prostate cancer incidence and disease-specific survival of men with ini-tial prostate-specific antigen less than 3.0 ng/ml who are par-ticipating in ERSPC Rotterdam. Eur Urol 2011; 59(4): 498−505.

van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, et al. Towards an optimal interval for prostate cancer screen-ing. Eur Urol 2012; 61(1): 171−6.